Trial Profile

Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 03 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Ivosidenib (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
Focus Adverse reactions

Most Recent Events

29 May 2026 Actual primary completion date changed from 8 Jan 2025 to 16 Jan 2022.
29 May 2026 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Low accrual
13 Jan 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com